Form 4: BeiGene Director Alessandro Riva Acquires Shares and Options

Director Alessandro Riva acquired shares and options in BeiGene, Ltd. on May 21, 2025, according to a Form 4 filing.

Summary

• On May 21, 2025, Alessandro Riva, a director of BeiGene, Ltd., acquired 10,985 ordinary shares at $0 and was granted options to purchase 22,750 ordinary shares at an exercise price of $18.19.
• Following these transactions, Riva beneficially owns 56,940 ordinary shares and options for 22,750 ordinary shares.
• The shares were acquired as restricted share units, which vest on the earlier of the first anniversary of the grant date or the next annual general meeting, with accelerated vesting upon a change in control or certain termination events.
• The options also vest on the earlier of the first anniversary of the grant date or the next annual general meeting, with similar accelerated vesting provisions.
• These transactions were made under the Company's Independent Director Compensation Policy, as amended.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. A director acquiring shares and options generally indicates confidence in the company, but it's a routine transaction.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future prospects.
• The vesting schedule incentivizes the director to remain with the company and contribute to its success.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the shares and options suggests a commitment to the company's long-term performance.

Industry Context

Director share acquisitions are common in the biopharmaceutical industry and are often seen as a positive sign of management's confidence in the company's future. This filing is a routine disclosure required by the SEC.

Comparison to Industry Standards

• Director compensation packages, including stock options and restricted share units, are standard practice in the biopharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar compensation structures to align the interests of their directors with those of shareholders.
• The vesting schedules and terms outlined in this filing are generally consistent with industry norms for director compensation.

Stakeholder Impact

• Shareholders may view the director's share acquisition as a positive signal.
• Employees may see it as a sign of stability and confidence in the company's leadership.

Key Dates

Keywords

BeiGene, Director, Alessandro Riva, Share Acquisition, Stock Options, Form 4, Beneficial Ownership, Vesting, Independent Director Compensation Policy